Free Light Chain Assay Using Reducing Agent Separation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing assays for free light chains (FLC) face limitations due to the presence of polymeric forms, which can lead to underestimation or overestimation of monoclonal FLC concentrations, affecting diagnostic accuracy.
Innovation Solution
A method is developed to selectively separate multimeric free light chains into monomeric forms using a separating agent, such as a reducing agent, without damaging antibodies or intact immunoglobulins, and then quantify the monomeric analyte using an analyte-specific binding agent.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If polymeric free light chains are measured directly in existing assays, then the assay can be performed without additional treatment steps, but the measurement precision is compromised due to underestimation or overestimation of monoclonal FLC concentrations
Solution Approach 1:
The patent applies preliminary action by treating the sample with a reducing agent before the assay to convert polymeric free light chains into monomeric forms. This pre-treatment step ensures that the subsequent measurement reflects the true monoclonal FLC concentration without interference from polymeric forms, thereby resolving the contradiction between assay simplicity and measurement precision.
Solution Approach 2:
The patent changes the physical-chemical state of the free light chains from polymeric to monomeric form through reduction treatment. This parameter change (molecular size, structure) allows the assay to accurately measure monoclonal FLC concentrations without the measurement errors caused by polymeric forms, while maintaining assay efficiency.
2Measurement precision
If a reducing agent is used to separate multimeric free light chains into monomeric forms, then measurement precision is improved, but the device complexity increases due to additional treatment steps
Solution Approach 1:
The patent merges the reduction treatment step with the existing assay procedure by incorporating the reducing agent treatment as an integrated pre-treatment step. The reducing agent is added to the sample before the assay reagents, and the same reaction mixture is used for both separation and subsequent measurement, thereby combining multiple functions into a single workflow and minimizing the increase in procedural complexity.
Solution Approach 2:
The reducing agent serves multiple functions: it separates multimeric free light chains into monomeric forms, prevents re-association during the assay, and maintains the monomeric state throughout the measurement process. This multi-functionality reduces the need for additional separate steps, thereby limiting the increase in device complexity while achieving improved measurement precision.
3Quantity of substance
If polymeric free light chains are present in the sample, then the total FLC amount is increased, but the reliability of the assay is reduced due to underestimation or overestimation of monoclonal FLC
Solution Approach 1:
The patent extracts the polymeric free light chains from the total FLC mixture by using a reducing agent to break the disulfide bonds that maintain the polymeric structure. This extraction separates the polymeric forms from the monomeric forms, allowing the assay to specifically measure the monoclonal FLC concentration without the interfering effect of polymeric forms, thereby improving diagnostic accuracy while accounting for total FLC amount.
Solution Approach 2:
The reducing agent acts as an intermediary substance that facilitates the conversion of polymeric free light chains into monomeric forms. It temporarily introduces a chemical modification (reduction of disulfide bonds) that enables the subsequent accurate measurement of monoclonal FLC, and this intermediary effect is reversed or stabilized during the assay to ensure reliable diagnostic results.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach improves the accuracy of FLC assays by ensuring that both the sample and calibrator are treated consistently, reducing the impact of polymerization on measurement results, and allowing for precise determination of multimeric analyte concentrations.
Implementation Method 1
treating the multimeric analyte with a separating agent selected to convert at least a portion of the multimeric analyte into monomeric analyte
Data Source
AI summary
The application describes a method of quantifying a multimeric analyte in a sample comprising: (i) treating the multimeric analyte with a separating agent selected to convert at least a portion of the multimeric analyte into monomeric analyte; (ii) binding the analyte to an analyte-specific binding agent; (iii) comparing the amount of binding of the analyte to the analyte-specific binding agent to a calibration curve, wherein the calibration curve is obtained (i) by binding the analyte-specific binding agent to one or more predetermined amounts of separating agent treated analyte, prior to contacting with analyte-specific binding agent or (ii) by binding the analyte-specific binding agent to a predetermined amount of substantially monomeric analyte; and (iv) determining an amount of the multimeric analyte in the sample.